Skip to main content
. 2016 Nov 10;6:36721. doi: 10.1038/srep36721

Figure 1. The effect of solamargine and metformin on growth of CRPC cells.

Figure 1

(A) CRPC cell lines (PC3, DU145 and C4-2B) and one human benign prostate hyperplasia epithelial cell line (BPH-1) were treated with increased concentrations of solamargine for up to 72. Afterwards, the cell viability was determined using the MTT assay as described in the Materials and Methods Section. (B,C), Prostate cancer cells PC3 and C4-2B were treated with increased concentrations of solamargine for up to 48 h. Afterwards, the cells were collected and processed for analysis of cell cycle distribution by flow cytometry after propidium iodide (PI) staining. And the percentages of the cell population in each phase (G0/G1, S and G2/M) of cell cycle were assessed by Multicycle AV DNA Analysis Software. Data are expressed as a percentage of total cells. Values are given as the mean ± SD from 3 independent experiments performed in triplicate. (D) PC3 and DU145 cells were treated with solamargine (6 μM) and metformin (5 mM) for 48 h. Afterwards, the cell viability was determined using the MTT assay. (E) PC3 cells were treated with compound C (10 μM) for 2 h before exposure the cells to solamargine (6 μM) for up to 48 h. Afterwards, the cell viability was determined using the MTT assay. *indicates significant difference as compared to the untreated control group (P < 0.05). **Indicates significant difference from solamargine treated alone (P < 0.05).